These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 27710979)

  • 41. Reactive oxygen species may have antitumor activity in metastatic melanoma.
    Tuma RS
    J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
    [No Abstract]   [Full Text] [Related]  

  • 42. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury AF; El Sayed F; Bazex J
    Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
    [No Abstract]   [Full Text] [Related]  

  • 43. Combination chemotherapy with dacarbazine and vindesine in the treatment of metastatic malignant melanoma.
    Vorobiof DA; Sarli R; Falkson G
    Cancer Treat Rep; 1986 Jul; 70(7):927-8. PubMed ID: 3719588
    [No Abstract]   [Full Text] [Related]  

  • 44. Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.
    van den Brom RR; Mäkelburg AB; Schröder CP; de Vries EG; Hospers GA
    J Clin Oncol; 2015 Dec; 33(36):e133-4. PubMed ID: 24778390
    [No Abstract]   [Full Text] [Related]  

  • 45. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective.
    Goldstein DA; Zeichner SB
    Am J Manag Care; 2015 Sep; 21(10 Suppl):S234-41. PubMed ID: 26619297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRAF and MEK inhibition in melanoma.
    Dossett LA; Kudchadkar RR; Zager JS
    Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
    Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
    Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis?
    Reigneau M; Granel-Brocard F; Geoffrois L; Bauman AS; Tréchot P; Barbaud A; Schmutz JL
    Eur J Dermatol; 2013; 23(4):544-5. PubMed ID: 24001519
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term remissions in metastatic malignant melanoma following chemotherapy and tamoxifen maintenance.
    Metzner B; Casper J; Hartung G; Rosien B; Hölzle E; Pelzer P; Köhne CH
    Onkologie; 2011; 34(4):208-9. PubMed ID: 21447982
    [No Abstract]   [Full Text] [Related]  

  • 52. Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.
    Mangold AR; Bryce A; Sekulic A
    J Am Acad Dermatol; 2014 Nov; 71(5):e205-6. PubMed ID: 25437992
    [No Abstract]   [Full Text] [Related]  

  • 53. Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations.
    Yamazaki N; Kiyohara Y; Sugaya N; Uhara H
    J Dermatol; 2015 Jul; 42(7):661-6. PubMed ID: 25884515
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
    Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
    JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
    Meier F; Guenova E; Clasen S; Eigentler T; Forschner A; Leiter U; Zielinski C; Knaudt B; Garbe C; Berneburg M
    J Am Acad Dermatol; 2009 May; 60(5):863-8. PubMed ID: 19389529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
    Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
    Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
    Degen A; Völker B; Kapp A; Gutzmer R
    Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
    [No Abstract]   [Full Text] [Related]  

  • 59. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.